Secondary Acute Lymphoblastic Leukemia after Primary Solid Organ Malignancy: A SEER Analysis of Incidence and Outcomes

摘要: Background: The incidence of secondary Acute Lymphoblastic leukemia (sALL) after a preceding first primary solid organ malignancy (1M) is not well defined. We undertook Surveillance Epidemiology and End Results (SEER)-based analysis to describe the occurrence sALL among adult patients with history common 1M9s. also evaluated differences in survival on basis age, site extent 1M, for evidence any underlying racial/ethnic disparity. Methods: SEER-18 database (1973-2011) was interrogated current study. All confirmed cases ALL (ICD-O-3 codes: 9811, 9812, 9814-18, 9826-28, 9835-37) (age ≥18 years) were identified. De novo vs. determined by using SEER variable ‘First Malignant Primary Indicator9. 1M prior diagnosis identified merging all databases together patient ID number. Those stage ‘in situ9; reported Results: A total n=8,398 (1ALL) n=414 Patient characteristics significantly different between 1ALL & (Table). Males comprised 49.8% as compared 58% 1ALL. Age at different, 55.5% being ≥65 years 51.4% observed 18-44 age group. Non-Whites 27.3% 40.4% 1ALL, Hispanics having most differential distribution 13.3% 24.6%, respectively two groups. Distribution latency from shown Table. majority had local/regional (rather than advanced stage) inferior OS when (HR 1.211, 95%CI 1.079-1.359) (Median 14 months 18 months, Figure). longer interval (>5 year) appeared have better median shorter intervals, but this difference statistically significant (p=0.53). Conclusion: performed largest population-based identifying demonstrating that are older worse noted lower relative while converse true Whites. Although detailed treatment data (specifically respect chemotherapeutic agents) available SEER, it possible - presumably adjuvant nature may be associated risk sALL. Further analyses required ongoing confirm specific 1M9s, impact both modalities era developing Disclosures No relevant conflicts interest declare.